Anterogen: Japanese Approval for EB Therapy AlloStem and Revenue Growth

In April 2026, obtained Japanese PMDA approval for regenerative medicine product 'AlloStem' for epidermolysis bullosa (EB)
Q1 2026 revenue KRW 2.12bn (vs. KRW 1.60bn YoY, +32%), operating loss KRW 1.10bn (vs. KRW 1.09bn YoY), net loss KRW 0.88bn (vs. KRW 0.70bn YoY)
R&D expenses KRW 1.29bn (61% of revenue), cash & equivalents ~KRW 42.68bn, debt ratio 1.1% (net cash)
Key pipeline: Cupistem (marketed), ALLO-ASC-DFU (Phase 3 Korea/Phase 2 US), ANT-301 (Phase 1 Korea), ANT-501 (preclinical)
No share buyback/cancellation or dividend plan disclosed